Nutraveris

Angelica gigas Nakai extract supplementation improves blood triglycerides and may be considered to prevent hypertriglyceridemia

This randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the effects of an extract of Angelica gigas Nakai (AGNE) on blood triglycerides (TG).

To do so, 100 Korean subjects (130 mg/dL ≤ fasting blood TG ≤ 200 mg/dL) were randomized to receive either 1 g/day of AGNE (as A. gigas Nakai extract 200 mg/d) or a placebo for 12 weeks.

Outcomes were efficacy TG, lipid profiles, atherogenic index, and safety parameters.

Results showed that TG, free fatty acids and very low-density lipoprotein cholesterol (VLDL-C) concentration and TG/HDL-C ratio in the AGNE group were significantly reduced compared to the placebo group (p < 0.05). There were no statistically significant differences between the groups for any other variables. No significant changes in any safety parameter were observed.

In conclusion, ingestion of AGNE for 12 weeks is safe and may improve blood triglycerides and be useful to manage or prevent hypertriglyceridemia.

Jung SJ, Kim WR, Oh MR, Cha YS, Park BH, Chae SW. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Assessing the Effects of Angelica Gigas Nakai Extract on Blood Triglycerides. Nutrients. 2020;12(2):E377.

Data Solution

The most efficient DATA Solution to create your products in the 28 European Member States

Compliance

The artificial intelligence solution for regulatory review & labelling. Enter your formula and start the analysis!